Mach 1 Financial Group LLC Buys Shares of 6,010 DexCom, Inc. (NASDAQ:DXCM)

Mach 1 Financial Group LLC purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 6,010 shares of the medical device company’s stock, valued at approximately $746,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in DXCM. Valeo Financial Advisors LLC increased its position in shares of DexCom by 43.9% during the 3rd quarter. Valeo Financial Advisors LLC now owns 2,364 shares of the medical device company’s stock valued at $221,000 after purchasing an additional 721 shares during the last quarter. Commonwealth Equity Services LLC increased its position in shares of DexCom by 1.5% during the 3rd quarter. Commonwealth Equity Services LLC now owns 43,769 shares of the medical device company’s stock valued at $4,084,000 after purchasing an additional 635 shares during the last quarter. Cambridge Investment Research Advisors Inc. increased its position in shares of DexCom by 24.6% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 26,463 shares of the medical device company’s stock valued at $2,469,000 after purchasing an additional 5,222 shares during the last quarter. Kingswood Wealth Advisors LLC purchased a new stake in DexCom in the 3rd quarter worth approximately $441,000. Finally, Xponance Inc. increased its holdings in DexCom by 2.0% in the 3rd quarter. Xponance Inc. now owns 88,603 shares of the medical device company’s stock worth $8,267,000 after acquiring an additional 1,701 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Trading Up 1.3 %

NASDAQ DXCM traded up $1.58 on Tuesday, hitting $127.39. 3,049,135 shares of the stock were exchanged, compared to its average volume of 3,056,698. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. The stock has a fifty day moving average price of $131.49 and a two-hundred day moving average price of $119.53. The firm has a market capitalization of $50.66 billion, a P/E ratio of 82.19, a P/E/G ratio of 2.11 and a beta of 1.20. DexCom, Inc. has a 52-week low of $74.75 and a 52-week high of $142.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. The company had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. Research analysts forecast that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on DXCM. Raymond James increased their target price on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a report on Friday. UBS Group increased their target price on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Citigroup increased their target price on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Canaccord Genuity Group lifted their price objective on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research report on Friday. Finally, Royal Bank of Canada assumed coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and an average target price of $141.67.

Insiders Place Their Bets

In other DexCom news, EVP Sadie Stern sold 20,321 shares of DexCom stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the completion of the transaction, the executive vice president now directly owns 80,441 shares of the company’s stock, valued at $10,747,722.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Sadie Stern sold 20,321 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the completion of the sale, the executive vice president now directly owns 80,441 shares of the company’s stock, valued at $10,747,722.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Jereme M. Sylvain sold 3,363 shares of the business’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total transaction of $392,562.99. Following the sale, the chief financial officer now directly owns 71,142 shares of the company’s stock, valued at $8,304,405.66. The disclosure for this sale can be found here. Insiders sold 189,375 shares of company stock valued at $25,530,859 over the last three months. 0.41% of the stock is owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.